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Background: Surveillance of individuals at high risk of pancreatic ductal adenocarcinoma (PDAC) and its
precursors might lead to better outcomes. The aim of this study was to determine the prevalence
and outcomes of PDAC and high-risk neoplastic precursor lesions among such patients participating
in surveillance programmes.
Methods: A multicentre study was conducted through the International CAncer of the Pancreas Screen-
ing (CAPS) Consortium Registry to identify high-risk individuals who had undergone pancreatic resec-
tion or progressed to advanced PDAC while under surveillance. High-risk neoplastic precursor lesions
were defined as: pancreatic intraepithelial neoplasia (PanIN) 3, intraductal papillary mucinous neoplasia
(IPMN) with high-grade dysplasia, and pancreatic neuroendocrine tumours at least 2 cm in diameter.
Results: Of 76 high-risk individuals identified in 11 surveillance programmes, 71 had undergone surgery
and five had been diagnosed with inoperable PDAC. Of the 71 patients who underwent resection, 32
(45 per cent) had PDAC or a high-risk precursor (19 PDAC, 4 main-duct IPMN, 4 branch-duct IPMN,
5 PanIN-3); the other 39 patients had lesions thought to be associated with a lower risk of neoplastic
progression. Age at least 65 years, female sex, carriage of a gene mutation and location of a lesion in the
head/uncinate region were associated with high-risk precursor lesions or PDAC. The survival of high-risk
individuals with low-risk neoplastic lesions did not differ from that in those with high-risk precursor
lesions. Survival was worse among patients with PDAC. There was no surgery-related mortality.
Conclusion: A high proportion of high-risk individuals who had surgical resection for screening- or
surveillance-detected pancreatic lesions had a high-risk neoplastic precursor lesion or PDAC at the
time of surgery. Survival was better in high-risk individuals who had either low- or high-risk neoplastic
precursor lesions compared with that in patients who developed PDAC.
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Introduction
Despite improvements in treatments for pancreatic duc-
tal adenocarcinoma (PDAC), it remains the third leading
cause of cancer death in theUSA, with a 5-year survival rate
of only 8 per cent1. By 2030, PDAC is projected to become
the second leading cause of cancer-related death in the
USA2. Advances in screening, prevention and treatment
have the potential to change pancreatic cancer incidence
and death rates2. Inherited susceptibility is thought to be
a major factor in the development of PDAC, accounting
for 5–10 per cent of cases3. Surveillance for PDAC and
its precursor lesions in asymptomatic high-risk individuals
is increasingly being performed worldwide4–15. These
high-risk individuals can be categorized into two groups:
carriers of known PDAC-associated gene mutations
(especially carriers of deleterious mutations in CKDN2A,
BRCA2, BRCA1, ATM, TP53, PRSS1 or STK11), and
first-degree relatives in familial PDAC (clustering of at
least 2 first-degree blood relatives with PDAC)16. The
goals of surveillance have been described previously17
by the International CAncer of the Pancreas Screening
(CAPS) Consortium. They include: detection and treat-
ment of early invasive pancreatic cancer (T1N0M0) at
baseline or follow-up; detection and treatment of any inva-
sive resectable cancer at baseline screening; detection and
treatment of multifocal pancreatic intraepithelial neoplasia
(PanIN) 3; and the detection and treatment of intraductal
papillary mucinous neoplasia (IPMN) with high-grade
dysplasia.
Few studies have described the surgical pathology find-
ings in high-risk patients who have undergone surgery15,18.
The CAPS Consortium Registry was created to gather
information rapidly about the experience of surveillance.
In this study, the diagnostic yield and outcomes of high-risk
individuals who underwent surgical resection or progressed
to invasive cancer were evaluated, and the characteristics
of patients who developed high-risk neoplastic precursor
lesions or PDAC were examined.
Methods
All participating centres in the CAPS Consortium
(36 centres in 9 countries) were requested to enter
patient information data for high-risk individuals par-
ticipating in their PDAC surveillance programmes
who had either undergone pancreatic surgery because
of the detection of a suspicious pancreatic lesion, or
progressed to advanced unresectable malignant dis-
ease. Data were collected through the use of web-based
electronic data capture software (OmniComm Europe,
Bonn, Germany). Anonymized clinical and demographic
information was collected relating to age, sex, tobacco
and alcohol use, diabetes mellitus, history of pancreatitis,
BMI, known gene mutations, and family history of PDAC.
In addition, pancreatic imaging modalities that detected
the lesions, characteristics of the lesions detected by imag-
ing, timing of detection, therapy, pathology, and outcomes
after surgery or diagnosis of advanced PDAC were also
recorded.
Research protocols of all participating centres were based
largely on the consensus statements of the CAPS Consor-
tium, produced in 201317, acknowledging that the nature
of this study and its timespan made it inevitable that differ-
ences between protocols of screening centres would exist.
Index and follow-up examinations were carried out using
MRI and/or endoscopic ultrasonography. However, when
suspect lesions were detected, othermodalities, such as CT,
were often used for further characterization and staging.
All individuals in this study provided written informed
consent for their participation in the respective PDAC
surveillance programmes as approved by the ethics
committees of the participating centres. The study was
conducted in accordance with the Declaration of Helsinki.
Participants with pathologically proven high-risk neo-
plastic precursor lesions or PDAC were compared with
those who had surgery but in whom the resection spec-
imen harboured no high-risk precursor lesion or PDAC.
High-risk neoplastic precursor lesions were defined as uni-
focal ormultifocal PanIN-3 lesions, main- and branch-duct
IPMNswith high-grade dysplasia, and pancreatic neuroen-
docrine tumours (PanNETs) at least 2 cm in size19,20.
Statistical analysis
Descriptive statistics were used to characterize patient
and lesion characteristics. Univariable analyses (χ2 or
Fisher’s exact test where indicated for categorical variables,
independent-samples t test for continuous variables) were
performed on possible risk factors associated with PDAC
or high-risk neoplastic precursor lesions. All variables
with P< 0⋅200 in univariable analysis were included in the
multivariable analysis. Survival comparisons for different
subgroups were plotted as Kaplan–Meier curves, and
hazard ratios calculated using the log rank test. All analy-
ses were conducted using SPSS® version 21 (IBM,
Armonk, New York, USA).
Results
A total of 76 high-risk individuals were included from 11
PDAC surveillance programmes in four countries (USA,
the Netherlands, Israel and Italy). Between the 11 cen-
tres, some 1700 patients considered to be at high risk
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Table 1 Baseline characteristics of high-risk individuals who had surgery after detection of a suspicious pancreatic lesion or were
diagnosed with advanced pancreatic cancer
High-risk individuals
who had surgery (n = 71)
High-risk individuals
diagnosed with advanced
PDAC (n = 5)
Age at surgery or diagnosis (years)* 60⋅3(11⋅6) (59⋅8; 36–80) 70⋅5(6⋅6) (65–80)
Sex ratio (M :F) 37 : 34 1 : 4
Ethnicity
White 67 (94) 5 (100)
Black 3 (4) -
Other 1 (1) –
Genetic background
Familial pancreatic cancer 52 (73) 4 (80)
CDKN2A (FAMMM syndrome) 7 (10) –
BRCA2 (HBOC) 3 (4) –
Peutz–Jeghers syndrome 3 (4) 1 (20)
BRCA1 (HBOC) 1 (1) –
TP53 (Li–Fraumeni syndrome) 1 (1) –
MMR (Lynch syndrome) 1 (1) –
APC 1 (1) –
ATM 1 (1) –
PRRS1 (hereditary pancreatitis) 1 (1) –
No. of ﬁrst-degree relatives with PDAC* 1⋅5(0⋅8) (1⋅0; 0–3) 1⋅4(0⋅9) (0–2)
No. of second-degree relatives with PDAC* 1⋅1(1⋅0) (1⋅0; 0–4) 0⋅3(0⋅6) (0–1)
Youngest family member affected by PDAC* 55⋅5(10⋅8) (33–77) 63⋅3(7⋅5) (52–68)
BMI (kg/m2)* 27⋅3(5⋅1) (26⋅6; 18–48) 26⋅1(3⋅7) (23–31)
Personal history of diabetes 11 (15) 2 (40)
Duration of diabetes before surgery or diagnosis (months)* 36⋅6(23⋅7) (45⋅0; 0–63) 66⋅0(76⋅4) (12–120)
Personal history of pancreatitis 9 (13) 1 (20)
Smoking behaviour
Never smoker 46 (65) 3 (60)
Former smoker 20 (28) 2 (40)
Current smoker 3 (4) –
No data 2 (3)
≥10 pack-years in total 11 (15) 1 (20)
≥20 pack-years in total 4 (6) –
Alcohol consumption
Never consumer 38 (54) 2 (40)
Former consumer 12 (17) 1 (20)
Current consumer 19 (27) 2 (40)
No data 2 (3) –
≥10units per week (current or past) 5 (7) –
≥20units per week (current or past) 2 (3) –
Values in parentheses are percentages unless indicated otherwise; *values are mean(s.d.) (median; range). PDAC, pancreatic ductal adenocarcinoma;
FAMMM, familial atypical multiple mole melanoma syndrome; HBOC, hereditary breast and ovarian cancer; MMR, mismatch repair genes; APC,
adenomatous polyposis coli; ATM, ataxia telangiectasia mutated.
underwent surveillance, of whom approximately 70 per
cent were women. Of the 76 included, five were diagnosed
with advanced disease during surveillance and 71 under-
went surgery for a suspected lesion, of whom two were dis-
covered to have inoperable disease. Baseline characteristics
for all 76 high-risk individuals are summarized in Table 1.
High-risk neoplastic precursor lesions
and (advanced) pancreatic ductal adenocarcinoma
High-risk neoplastic precursor lesions or PDAC were
present in the surgical specimens of 32 (45 per cent) of the
71 patients who had surgery. Among these, five patients
(7 per cent) had PanIN-3 lesions as the highest-grade
© 2019 The Authors. www.bjsopen.com BJS Open 2019; 3: 656–665
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Table 2 Overview of lesion characteristics, type of surgery and pathology in high-risk individuals who had surgery after detection of a






PDAC (n = 5)
Lesion characteristics
Time point of lesion detection
Baseline 39 (55) 2 (40)
Follow-up 32 (45) 3 (60)
Present at previous investigations 9 (13) 1 (20)
Duration of lesion visualization before resection/diagnosis (months)* 8⋅7(9⋅5) (5⋅0; 1–32) 41(41)
Overdue for recommended screening 10 (14) 1 (20)
Months overdue for recommended screening* 6⋅7(3⋅4) (6⋅0; 1–12) 3(3)
Modality that detected the lesion†
EUS 62 (87) 2 (40)
MRI/MRCP 29 (41) 3 (60)
CT/PET–CT 28 (39) 2 (40)
ERCP 8 (11) 0 (0)




Dilated pancreatic duct 2 (2)
Features of chronic pancreatitis 1 (1)
Other 10 (11)
Location of lesion (n = 93)
Head/uncinate region 35 (38)
Body 20 (22)
Tail 29 (31)
No data 9 (10)
Size of lesion size (mm)*
All lesions (n = 93) 14⋅0(8⋅8) (11⋅9; 3–51)
Cystic lesions (n = 44) 13⋅6(8⋅0) (11⋅6; 3–40)
Solid lesions (n = 33) 15⋅5(10⋅0) (13⋅0; 4–51)
Neoadjuvant therapy 4 (6) n.a.
Type of surgery n.a.
Distal pancreatectomy 36 (51)
Pancreatoduodenectomy 18 (25)
Total pancreatectomy 9 (13)
Pancreatoduodenectomy then completion pancreatectomy 4 (6)
Central pancreatectomy 2 (3)
Diagnosis of unresectable disease during surgery 2 (3)
Complications of surgery† n.a.
None 37 (52)
Infectious complications 10 (14)
Delayed gastric emptying 6 (8)
Pancreatic fistula 4 (6)
Bile leak 2 (3)
Peripancreatic fluid collection 1 (1)
Other 6 (8)
No data 7 (10)
Pathology†
PDAC 19 (27) 5 (100)
Main-duct IPMN with high-grade dysplasia 1 (1) –
Main-duct IPMN with moderate-grade dysplasia 4 (6) –
© 2019 The Authors. www.bjsopen.com BJS Open 2019; 3: 656–665
BJS Open published by John Wiley & Sons Ltd on behalf of BJS Society Ltd







PDAC (n = 5)
Main-duct IPMN with low-grade dysplasia 1 (1) –
Mixed-duct IPMN with high-grade dysplasia 1 (1) –
Mixed-duct IPMN with moderate-grade dysplasia 0 (0) –
Mixed-duct IPMN with low-grade dysplasia 0 (0) –
Branch-duct IPMN with high-grade dysplasia 5 (7) –
Branch-duct IPMN with moderate-grade dysplasia 9 (13) –
Branch-duct IPMN with low-grade dysplasia 16 (23) –
PanIN-3, multifocal 3 (4) –
PanIN-3, unifocal 3 (4) –
PanIN-2, multifocal 35 (49) –
PanIN-2, unifocal 10 (14) –
PanIN-1, multifocal 32 (45) –
PanIN-1, unifocal 4 (6) –
Pancreatic neuroendocrine tumour ≥2 cm 0 (0) –
Pancreatic neuroendocrine tumour <2 cm 8 (11) –
Incipient IPMN 5 (7) –
Serous cystadenoma 2 (3) –
Vascular malformation 1 (1) –
Highest grade of neoplastic lesion per high-risk individual
PDAC 19 (27) 5 (100)
Stage I/II 16 (23) 0 (0)
Stage III/IV 3 (4) 5 (100)
Main-duct IPMN with high-grade dysplasia 1 (1) –
Main-duct IPMN with moderate-grade dysplasia 2 (3) –
Main-duct IPMN with low-grade dysplasia 1 (1) –
Branch-duct IPMN with high-grade dysplasia 4 (6) –
Branch-duct IPMN with moderate-grade dysplasia 7 (10) –
Branch-duct IPMN with low-grade dysplasia 9 (13) –
PanIN-3, multifocal 3 (4) –
PanIN-3, unifocal 2 (3) –
PanIN-2, multifocal 9 (13) –
PanIN-2, unifocal 7 (10) –
PanIN-1, multifocal 1 (1) –
PanIN-1, unifocal 1 (1) –
Pancreatic neuroendocrine tumour <2 cm 3 (4) –
Serous cystadenoma 2 (3) –
Values in parentheses are percentages unless indicated otherwise; *values are mean(s.d.) (median; range). †More than one option possible. PDAC, pan-
creatic ductal adenocarcinoma; EUS, endoscopic ultrasonography; MRCP, magnetic resonance cholangiopancreatography; ERCP, endoscopic retrograde
cholangiopancreatography; n.a., not applicable; IPMN, intraductal papillary mucinous neoplasm; PanIN, pancreatic intraepithelial neoplasia.
neoplastic lesion, four (6 per cent) had a branch-duct
IPMN with high-grade dysplasia, four (6 per cent) had a
main-duct IPMN, and 19 (27 per cent) had PDAC. Pathol-
ogy findings in all 71 high-risk individuals who underwent
surgery are summarized in Table 2, as well as lesion charac-
teristics and types of surgery.
In 39 high-risk individuals (55 per cent), the indication
for surgery was detected at the baseline screening evalu-
ation. In the remaining 32 patients (45 per cent), lesions
were detected at follow-up investigations; in nine of these,
a lesion had already been present at previous investigations,
for a mean of 9months before resection. These lesions
initially did not meet resection criteria, but a changing
appearance over time led to resection. For ten of these 32
patients there was a mean delay of 7months from their
recommended screening interval (this ranged from 3 to
24months, depending on visualization and type of lesion).
Endoscopic ultrasonography detected the vast majority of
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Table 3 Outcomes in high-risk individuals who had surgery or were diagnosed with advanced disease
High-risk individuals
who had surgery (n = 71)
High-risk individuals
diagnosed with advanced
PDAC (n = 5) P†
Duration of follow-up (months)* 51⋅6(45⋅1) (42⋅0; 0–168) 8⋅2(11⋅1) (3⋅0; 3–28) <0⋅001‡
Survival
Alive 59 (83) 2 (40) 0⋅050
Time after surgery/diagnosis (months)* 54⋅3(45⋅9) (44⋅0; 0–168) 9⋅5(12⋅3) (3⋅5; 3–28) <0⋅001‡
Long-term survival (≥3 years) 37 (52) 0 (0)
Mortality
Died 12 (17) 3 (60) 0⋅050
Time after surgery/diagnosis (months)* 54⋅3(56⋅0) (28⋅5; 5–164) 11⋅3(14⋅4) (3⋅0; 3–28) 0⋅221‡
Short-term mortality (≤1 year) 2 (3) 2 (40) 0⋅154
PDAC-related 8 (11) 3 (60) 0⋅506
Not PDAC-related 2 (3) 0 (0)
Unknown cause of death 2 (3) 0 (0)
Values in parentheses are percentages unless indicated otherwise; *values are mean(s.d.) (median; range). PDAC, pancreatic ductal adenocarcinoma. †χ2 or
Fisher’s exact test, except ‡independent-samples t test.
Table 4 Univariable and multivariable analysis of factors possibly associated with high-risk neoplastic precursor lesions or pancreatic
ductal adenocarcinoma in the resection specimen
Univariable analyses Multivariable analyses
Unadjusted OR P Adjusted OR P
Age≥65 years at surgery 4⋅11 (1⋅44, 11⋅70) 0⋅007 7⋅53 (1⋅6, 35⋅0) 0⋅010
Female sex 3⋅82 (1⋅42, 10⋅25) 0⋅007 5⋅78 (1⋅4, 24⋅3) 0⋅017
White ethnicity 0⋅25 (0⋅03, 2⋅57) 0⋅321
Carrier of a gene mutation 2⋅40 (0⋅80, 7⋅16) 0⋅113 4⋅92 (1⋅1, 22⋅6) 0⋅040
≥2 first-degree relatives affected by PDAC 2⋅40 (0⋅91, 6⋅36) 0⋅076 1⋅71 (0⋅4, 7⋅2) 0⋅462
Family member aged <50 years affected by PDAC 1⋅15 (0⋅34, 3⋅85) 0⋅820
BMI ≥25 kg/m2 0⋅57 (0⋅20, 1⋅67) 0⋅303
Personal history of diabetes 1⋅83 (0⋅49, 6⋅77) 0⋅505
Personal history of pancreatitis 0⋅69 (0⋅16, 3⋅03) 0⋅727
Current or former smoker 1⋅00 (0⋅36, 2⋅75) 1⋅000
>10 pack-years of smoking 0⋅95 (0⋅14, 6⋅28) 1⋅000
Current or former consumption of alcohol 0⋅70 (0⋅27, 1⋅84) 0⋅470
Detection of lesion at follow-up visit 1⋅14 (0⋅45, 2⋅92) 0⋅782
Solid lesion type (versus cystic lesion) 1⋅11 (0⋅40, 3⋅07) 0⋅839
Location of lesion in head/uncinate region (versus location in body/tail) 2⋅33 (0⋅83, 6⋅56) 0⋅105 4⋅23 (1⋅1, 16⋅9) 0⋅041
Lesion size ≥1 cm 1⋅26 (0⋅39, 4⋅12) 0⋅702
Surgery after 2011 1⋅47 (0⋅54, 4⋅01) 0⋅448
Values in parentheses are 95 per cent confidence intervals. OR, odds ratio; PDAC, pancreatic ductal adenocarcinoma.
lesions (87 per cent). A total of 93 suspicious lesions were
detected in the 71 patients who underwent surgery, of
which 44 (47 per cent) were cystic and 33 (35 per cent) were
solid in appearance. The mean size of these 93 lesions was
14⋅0 (range 3–51) mm.
Distal pancreatectomy was performed in 36 patients
(51 per cent) and pancreatoduodenectomy in 18 (25 per
cent). Complications of surgery were seen in 34 patients
(48 per cent). The most common complications were
infection (14 per cent), delayed gastric emptying (8 per
cent) and pancreatic fistula (6 per cent). There were no
surveillance or surgery-related deaths.
Of the five patients diagnosed with advanced disease
during surveillance, three (60 per cent) were identified
at follow-up; the other two were detected at baseline
evaluation.
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Group 1, low-risk neoplastic lesions including pancreatic neuroendocrine tumours smaller than 2 cm; group 2, high-risk neoplastic lesions including all
main-duct intraductal papillary mucinous neoplasms (IPMNs), branch-duct IPMNs with high-grade dysplasia and pancreatic intraepithelial neoplasia type
3 lesions; group 3, stage I–II pancreatic ductal adenocarcinoma (PDAC); group 4, stage III–IV PDAC.
Outcomes
The outcomes for both risk groups are summarized
in Table 3. Of all 76 included patients, 61 (80 per cent)
are still alive a mean 52months after surgery or diagnosis
of PDAC. Of 71 high-risk individuals who underwent
surgery, 59 (83 per cent) were still alive after a mean
follow-up of 54⋅3months. Of the 12 patients who died,
eight deaths were PDAC-related. The survival rate was
significantly poorer for individuals with advanced PDAC
compared with those who had surgery (40 versus 83 per
cent respectively, P = 0⋅050; mean survival 9⋅5 versus
54⋅3months, P< 0⋅001). Only two (3 per cent) of the 71
high-risk patients who underwent surgery died within
1 year (all-cause 1-year mortality), compared with two of
five patients with advanced PDAC; 52 per cent survived
for 3 years or more after surgery.
Risk factors
Univariable analysis of factors associated with high-risk
neoplastic precursor lesions or PDAC in the resection
specimen included age 65 years or more at the time
of surgery (odds ratio (OR) 4⋅11; P = 0⋅007) and female
sex (OR 3⋅82; P = 0⋅007) (Table 4). In multivariable anal-
ysis, four factors were significantly associated with the
presence of a high-risk precursor lesion or PDAC in the
pancreatic resection specimen: age 65 years or above at the
time of surgery (OR 7⋅53; P = 0⋅010), female sex (OR 5⋅78;
P = 0⋅017), carriage of a deleterious mutation in a known
pancreatic cancer susceptibility gene (OR 4⋅92; P = 0⋅040)
and location of a lesion in the head/uncinate region of the
pancreas (OR 4⋅23; P = 0⋅041).
Survival analysis
The pancreatic neoplasia grade was significantly associated
with overall survival in high-risk individuals. Fig. 1 shows
the Kaplan–Meier curves for different pathological sub-
groups. High-risk individuals with no or low-risk neoplas-
tic lesions (group 1; 39 patients) and high-risk individuals
with high-risk neoplastic precursor lesions (group 2; 13
patients) had the best survival, followed by those with stage
I or II PDAC (group 3; 16 patients), and those with stage
III or IV PDAC (group 4; 8 patients). The hazard ratio for
group 2was 4⋅52 (95 per cent c.i. 0⋅10 to 197⋅60; P = 0⋅163)
versus group 1, 13⋅12 (3⋅03 to 56⋅75; P< 0⋅001) versus group
3, and 25⋅33 (1⋅17 to 547⋅20; P< 0⋅001) versus group 4.
Discussion
In this multicentre international study, high-risk neoplas-
tic lesions or PDAC were present in 45 per cent of the
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high-risk population that underwent surgery in a PDAC
surveillance programme. Survival in high-risk patients
with no or low-risk lesions did not differ significantly from
that in patients with high-risk neoplastic precursor lesions.
The patients who developed PDAC had a significantly
higher overall mortality rate and poorer survival than those
with no or low-risk neoplastic lesions.
Surveillance of high-risk individuals has the potential
to improve the poor survival of patients with PDAC,
and is increasingly being undertaken. In 2010, the CAPS
Consortium was formed to help organize global pancreatic
surveillance. By pooling data from participating centres,
important research questions pertaining to pancreatic
surveillance can be assessed readily. The present analysis
reports the pooled data of high-risk individuals for whom
surveillance led to the detection of advanced disease or a
lesion for which pancreatic surgery was performed.
Goals of surveillance described previously by the CAPS
Consortium17 were early invasive cancers (T1N0M0),
PanIN-3, main-duct IPMNs and branch-duct IPMNs with
high-grade dysplasia. Although PanNETs of 2 cm or more
in size were also included in the definition, no such large
PanNETs were detected. Timing of intervention is an
important issue. In this series, 55 per cent of the resec-
tion specimens harboured no high-risk neoplastic precur-
sor lesion or PDAC, but did contain, for example, low-risk
PanIN lesions (PanIN-1 or -2) or small PanNETs. Only
long-term follow-up will disclose whether patients with
resected low-risk lesions might have a reduced risk of sub-
sequently developing PDAC. For some patients, surgical
resection was performed too late, as only three of the 19
PDACs had T1 status. The main challenge in any surveil-
lance programme is how to distinguish between individuals
who can bemonitored safely and those who require surgery
to resect a neoplastic lesion at a curable stage.
In this study, 55 per cent of lesions that prompted surgery
were detected at a baseline visit. This could raise the ques-
tion whether one-time screening of high-risk individuals at
a given age is also effective. Alternatively, when an advanced
lesion is found at the index investigation, it could be argued
that this lesion might have been detected at an earlier stage
with potentially a better outcome if surveillance had started
at an earlier age. As new lesions were detected in sev-
eral patients who missed their follow-up visit by only a
few months, it seems appropriate to adhere to an annual
surveillance protocol, until more data are available from
large prospective cohorts.
Although not all patients with main-duct IPMN progress
to cancer, the overall 10-year risk is estimated at approxi-
mately 25 per cent21. Only two patients in the present study
were identified with these lesions before surgery. After
pathological evaluation of the resection specimen four cys-
tic lesions were reclassified as main-duct IPMN. Discrep-
ancy between imaging and pathology is not an uncommon
finding in this situation22.
The present study also sought to identify risk factors
that can easily be assessed before surgery for association
with high-risk neoplastic precursor lesions or PDAC in the
resection specimens. Multivariable analyses showed age at
least 65 years, female sex, carriage of a gene mutation and
location of a lesion in the head/uncinate region of the pan-
creas to be associated with the detection of a high-risk pre-
cursor lesion or PDAC in the resection specimen. Among
female carriers of a gene mutation aged above 65 years with
a lesion suspicious for malignancy in the head/uncinate
region of the pancreas, the option of pancreatic surgery ver-
sus continuing surveillance should be weighed carefully.
Survival analysis indicated that this was strongly influ-
enced by the stage of disease at diagnosis23. Importantly,
the survival of patients with high-risk neoplastic precursors
in the resection specimen was similar to that of those with
no or low-risk neoplastic lesions, emphasizing the need
reliably to identify high-risk precursor lesions more than
early cancers.
The strength of this study is the international pooling
of data on PDAC surveillance programmes. This yielded
a unique and sizeable cohort of high-risk patients partic-
ipating in these programmes, in whom either a suspicious
lesion was detected for which they underwent surgery, or
in whom an inoperable pancreatic cancer developed. The
main limitations of this study are its design and potential
lead-time and length bias24. Another limitation is that
differences between protocols of the centres existed, par-
ticularly before publication of consensus statements of the
CAPS Consortium in 201317. Although this is the largest
cohort described, its sample size is still too limited to assess
differences in survival between R0 and R1 resections.
Another limitation is the lack of detailed information of
all 1700 high-risk individuals who underwent surveillance.
Attention was focused specifically on the highly selected
group of patients who either developed advanced neoplasia
or underwent pancreatic surgery, and this study has added
new, interesting and valuable data to the literature that
provides some rationale to screening individuals at high
risk for pancreatic cancer. More research is needed to
understand better the risk factors for individuals at high
risk of developing PDAC, and improve the selection of
high-risk individuals for surgery. International collabo-
ration in large worldwide prospective studies seems the
logical way forward.
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